1. Introduction {#s0005}
===============

Copy number variants are described in other neurodegenerative diseases such as hereditary sensory motor neuropathy (CMT1A), Alzheimer\'s disease (with Down syndrome), and Parkinson\'s disease [@bb0070], [@bb0045], [@bb0020]. Spinal muscular atrophy (SMA) and sporadic amyotrophic lateral sclerosis (SALS) are both motor neuron diseases. The former, a lower motor neuron disease is due to a reduced survival motor neuron (SMN) protein resulting from deletion of the *SMN1* gene and the inability of a highly similar gene, *SMN2* to compensate for the loss of *SMN1*. Abnormal *SMN1* copy number distribution in SALS provides additional evidence that gene copy number variants may also contribute to neurodegeneration in the disease [@bb0025]. The estimated incidence of SMA is 1/6000 to 1/10,000 live births and its carrier frequency is 1/30 to 1/50 in populations of European and Asian origin [@bb0085], [@bb0075], [@bb0090]. The rarity of SMA and unexpectedly high rate of alleles with three or more *SMN1* copies in individuals with black ancestry [@bb0040] have been reported [@bb0050], [@bb0100]. Despite a consanguinity rate of 17% and a number of patients diagnosed with other autosomal recessive neurological diseases, SMA is rare in Mali [@bb0055], [@bb0060]. SALS is an upper and lower motor neuron disease with an average incidence of 1.9 per 100,000/year and average prevalence of 5.2 per 100,000 in Western countries. The mean age of onset is 55--60 years and the mean duration is 4--5 years and riluzole is the only drug that has been shown to extend the survival [@bb0005], [@bb0110]. In the last decade, few cases of SALS have been suspected or diagnosed in Mali. In recent years, high *SMN1* copy number (*SMN1* gene duplications) has been proposed as a risk factor for the development and/or severity of SALS [@bb0105]. We hypothesize that Malians may be at a higher risk as compared with others.

2. Materials and methods {#s0010}
========================

We used the socio-demographic data from 420 of 632 Malian study participants who were sampled for our *SMN* copy number distribution study in which we determined the *SMN1* and *SMN2* copy number in genomic DNA samples from 391 Malian adult volunteers, 120 Yoruba from Nigeria, 120 Luyha from Kenya and 74 U.S. Caucasians using a Taqman quantitative PCR assay. We used *SMN* copy number data from 391 (with known *SMN1* and *SMN2* copy number) of 420 who consented for future use of their specimens and data. Our study participants were 69% male, 99% aged 18 to 29 years old and 97% single ([Table 1](#t0005){ref-type="table"}). We obtained information from a register to compile on ALS inpatients (Patient\#1 to Patient\#10) in the Neurology Department of the Teaching Hospital of Point G. We reviewed the physicians\' notes to obtain information for ALS outpatients (Patient\#11 to Patient\#15). We also used data generated from de-identified 120 Nigerian and 120 Kenyan samples from Coriell (Camden, NJ) as well as 74 anonymous U.S. Caucasians for control purpose in SMA related studies [@bb0060]. We calculated the cumulative copy number of *SMN1* and *SMN2* and estimated the SMN protein expression using the Veldink formula (*SMN1* copy number + 0.2 ∗* SMN2* copy number). We then calculated the relative risk (RR) for SALS using a 2 × 2 table.Table 1Socio-demographic description of our adult volunteer study participants.Socio-demographic dataFrequency (n)Percentage (%)SexMale29069Female13031Total420100Age group (in years)18--2941799.330--3520.5\> 3510.2Total420100Marital statusSingle40997.4Married112.6Total420100

3. Results {#s0015}
==========

3.1. Description of the study population {#s0020}
----------------------------------------

For the *SMN* copy number and sporadic ALS study in Malians, we used the stored data from 420 out of 632 study participants [@bb0060] who consented for the use of their specimens and data for future SMA and related studies. We found that our study participants were male in 69% of the cases, aged 18 to 29 years old in 99.3% of the cases and single in 97.3% of the cases ([Table 1](#t0005){ref-type="table"}).

3.2. Total *SMN* (*SMN1* + *SMN2*) copy number in Malians {#s0025}
---------------------------------------------------------

To check the distribution of the total *SMN* copy number, we calculated the cumulative copy number of *SMN1* and *SMN2* for each individual and the average *SMN1* or *SMN2* copy number in our study. We found that up to 15% (57/391) of Malians had 2 as a total *SMN* copy number and only 5% (20/391) had 6 or 7 total *SMN* copies ([Table 2](#t0010){ref-type="table"}). Fifty four percent (210/391) of the individuals had 4 or 5 total *SMN* copies. The average copy number of *SMN1* was 2.7 and the average copy number of *SMN2* was 1.1.Table 2A 2 × 2 table to determine the SALS odds ratio.Estimated SMN protein levelSALS patientsHealthy controls≤ 2.214763\> 2242175

3.3. SMN protein expression estimation based on Veldink formula {#s0030}
---------------------------------------------------------------

To evaluate the risk for amyotrophic lateral sclerosis (ALS) in our study population, we used a 2 × 2 table from the Veldink et al. 2005 paper to determine the SALS odds ratio ([Table 2](#t0010){ref-type="table"}) and estimated the SMN protein expression level using the Veldink formula. The cut off being 2.2, we found that 131 of 391 (33.5%) had an estimated SMN protein expression of ≤ 2.2; 60 out of 391 (15.3%) had an estimated SMN protein expression \< 2.2 and would be at risk of ALS according to Veldink et al. 2005 ([Table 3](#t0015){ref-type="table"}).Table 3Estimated SMN protein expression based on *SMN1* and *SMN2* copy number across various ethnicities using the Veldink formula.Estimated SMN proteinSub-Saharan Africa\*U.S. Caucasians (n = 74)Mali (n = 391)Nigeria (n = 120)Kenya (n = 120)≤ 260 (15.3%)15 (12.5%)11 (9.2%)6 (8%)2.1--2.371 (18.2%)38 (31.7%)25 (20.8%)21 (28%)2.4--4.6258 (66%)64 (53.3%)80 (66.7%)47 (64%)\> 4.62 (0.5%)3 (2.5%)4 (3.3%)0 (0%)[^1][^2]

3.4. Early onset and severe disease course in Malians with sporadic ALS {#s0035}
-----------------------------------------------------------------------

To characterize the disease natural history in Mali, we identified 15 ALS patients.

All patients were male, the disease onset was as early as 16 years old, and some patients were physically handicapped within 1--2 years in the disease course ([Table 4](#t0020){ref-type="table"}).Table 4Early onset of sporadic ALS and severe disease course in Malian ALS patients.Sporadic ALSAge at onset (years)Reason for consultationDisease severityCo-morbidityTreatment ReceivedDisease course/\
outcomePhysical handicapBulbar symptomsPatient 116Bilateral upper limb weakness and sorenessWasting of hands and arms at age 21Dysphagia (both liquid and solid) and dyspnea at age 21High blood pressureCortico-steroidsSpastic paraparesia at age 45\
Patient alivePatient 248TetraplegiaTetraplegia within 5 months after the onset of the diseaseHypernasalityNoneMuscle relaxantStationary disease evolution\*\*\*\
Patient alivePatient 325TetraparesiaTetraparesia predominant in the distality at age 28Dysphagia (liquid only) and HypernasalityBilateral inguinal herniaMulti-vitaminWorsening dysphagia\
Patient alivePatient 4\*38Left upper limb weaknessTetraplegia within 2 years after a head traumatismDysphagia (liquid only)Insomnia and lung infectionLarge spectrum antibioticsStationary disease evolution\
Patient alivePatient 539Bilateral lower limb weaknessSpastic paraparesia within one year of the onset of the diseaseIntermittent dysphagia, atophic tongue and slurred speechNoneSupportiveStationary disease evolution\
Patient alivePatient 6\*27Right upper limb weaknessTetraparesia within 11 months after the onset of the diseaseLingual fasciculationNoneMuscle relaxantStationary disease evolution\
Patient alivePatient 730Facial paresthesia and anorexiaFace atrophy and wasting of hands and arms within 2 yearsSlight dysphagia (solid only)\
Fasciculation and atrophy of the tongueLung infectionRiluzole 50 mg 1 tablet twice a dayStationary disease evolution\
Patient alivePatient 8\*24Wasting and muscle cramps of hands and armsWalking difficulty within a year after the onset of the diseaseDysphagiaNoneSupportiveStationary disease evolution\
Patient alivePatient 9\*\*55Right upper limb weaknessTetraplegia within 5 months of the onsetAbsentNoneTricyclic anti-depressantStationary disease evolution Patient alivePatient 1038Slurred speechWalking difficulty within 6 months after the onset of the diseaseDysphagia (liquid only) within 6 months after the onset of the diseaseLung infectionMuscle relaxantStationary disease evolution\
Patient alivePatient 1136Tetraparesia----NoneCortico-steroidsPatient died at age 37Patient 1248--Tetraparesia 6 months ago--NoneNonePatient alivePatient 1346------Hyper-glycemiaNonePatient alivePatient 1459----------Patient alivePatient 1566----------Patient alive[^3][^4]

4. Discussion {#s0040}
=============

Despite growing interest in recent years, the role of *SMN* copy number in SALS is still controversial. On the one hand, increased copies of *SMN1* have been reported to be associated with increased risk of SALS. Homozygous *SMN2* deletion is not a risk factor for ALS, and *SMN2* copy numbers have no effect on the disease [@bb0015], [@bb0025], [@bb0030], [@bb0080]. On the other hand, decreased *SMN* copy number has also been reported as a risk factor for SALS and low *SMN* protein level may play a role in the disease [@bb0105].

SMN protein levels can be estimated through the following formula: SMN protein = *SMN1* copy number + 0.2 × *SMN2* copy number [@bb0105]. We have two concerns with the Veldink formula: (i) the calculation is based only on *SMN* copy number instead of an accurate determination of SMN expression level. A new exonic splicing enhancer element in *SMN2*, c.859G \> C in exon 7 of the patients was identified and found to increase the amount of full-length SMN transcripts, thus resulting in less severe phenotypes [@bb0095] (ii) *SMN* hybrid genes (from *SMN1* to *SMN2* and vice versa) have been reported [@bb0060] with no information on how their *SMN* expression level. Therefore, it is not known whether all *SMN* copies in a given person are similar in structure and equally functional or not.

Nevertheless, one copy of *SMN1* was associated with an increased risk of developing ALS (odds ratio: 4.1, 95% CI: 1.2 to 14.2, p = 0.02). Sixty-one percent of 242 clinically well-defined SALS had an estimated SMN protein level of 2.2 or less as compared to only 36% healthy controls, suggesting that an estimated SMN protein of 2.2 or less was associated with a higher risk for SALS (odds ratio: 1.3, 95% CI: 1.1 to 1.6, p = 0.03) [@bb0105]. Using a 2 × 2 table, we estimated the relative risk (RR) to be 1.7 (147 × 175/242 × 63) ([Table 2](#t0010){ref-type="table"}). In other words, by extrapolation, 36 of 100 healthy controls and 61 of 100 SALS patients would have a low estimated SMN protein level. Based on Veldink\'s formula and this estimated RR, 60 out of our 391 study participants would be at a low risk of developing SALS. The onset of SALS is 40--60 years old in Europeans [@bb0010]. Our 60 healthy study participants at risk are only 18 to 26 years old ([Table 1](#t0005){ref-type="table"}) and the onset of the disease had a strikingly wide range from 18 to 66 years old in our SALS patients ([Table 4](#t0020){ref-type="table"}). Three patients, including two in their early 20s reported parental consanguinity, but the family history was negative. A thorough genetic study may be needed to exclude anticipation as the genetic risk factor for the early onset of the disease. Currently, it will be difficult for us to verify the predictability of the Veldink formula reliably due to the small number of our current SALS patients and adult volunteers estimated to be at risk of SALS. To determine the genetic risk factor, we plan to perform *SMN1* and *SMN2* copy number determination, *SOD1, C9orf72, FIG4* and *TDP* mutation screening in these patients. A long term follow-up of a larger Malian adult population at risk of SALS would answer this and other questions related to genetic risk. Regarding other risk and disease severity factors, only one case with a history of head trauma and smoking was found. We did not look for either a high ratio LDL/HDL resulting in a 12-month longer survival in ALS or hypercholesterolemia, which has been reported to result in 25% reduced the risk for ALS (Schmitt et al. 2014). Alternatively, with the increased number of adult neurologists in the country, which allow the compilation of our SALS patients ([Table 4](#t0020){ref-type="table"}), a good collaboration between neurologists in the teaching hospitals and researchers at the faculty of medicine will allow a careful screening for SALS among neurology outpatients and a subsequent *SMN* copy number quantification for SMN protein estimation in such patients.

5. Conclusion {#s0045}
=============

Due to the limited survival of our patients and our inability to establish family history and obtain DNA samples for a comprehensive genetic testing, our results are preliminary and inconclusive. In the future we plan to establish a network of neurologists and researchers for early ALS screening and genotype--phenotype correlation.
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[^1]: \*CEPH DNA + NIH BB samples.

[^2]: We used the Veldink formula (*SMN1* copy number + 0.2 ∗* SMN2* copy number) to estimate the SMN protein expression in 391 out of 420 study participants.

[^3]: \*Parental consanguinity \*\*history of smoking and alcoholism \*\*\*i.e., the disease did not worsen clinically from the first to the most recent outpatient visit or from the hospitalization to the hospital discharge.

[^4]: All patients were male.
